Detalhe da pesquisa
1.
Target-specific, histology-independent, randomized discontinuation study of lapatinib in patients with HER2-amplified solid tumors.
Invest New Drugs
; 30(2): 695-701, 2012 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-20857170
2.
Multi-omic molecular profiling guide's efficacious treatment selection in refractory metastatic breast cancer: a prospective phase II clinical trial.
Mol Oncol
; 16(1): 104-115, 2022 01.
Artigo
Inglês
| MEDLINE | ID: mdl-34437759
3.
Target-specific randomized discontinuation trial design: a novel approach in molecular therapeutics.
Invest New Drugs
; 28(2): 194-8, 2010 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-19262991
4.
Enrichment of PI3K-AKT-mTOR Pathway Activation in Hepatic Metastases from Breast Cancer.
Clin Cancer Res
; 23(16): 4919-4928, 2017 Aug 15.
Artigo
Inglês
| MEDLINE | ID: mdl-28446508